Idera Pharmaceuticals (IDRA +25.8%) ramps higher out of the gate after saying that its lead drug candidate IMO-3100, a treatment for moderate-to-severe plaque psoriasis, was more effective than a placebo in a Phase IIa clinical trial of two dose levels. The company thinks the trial data for the injectable treatment provides clinical proof-of-concept for the mechanism that suppresses certain factors that underlie the skin disorder.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs